40 results
6-K
EX-99.1
VALN
Valneva SE
20 Mar 24
Valneva Reports Full Year 2023 Results and Provides Business Updates and Outlook
12:52pm
of recruitment for Lyme disease Phase 3 study conducted in collaboration with PfizerAll execution milestones on track
Advancing second-generation ZIKA … .
Recruitment completion for the study was announced in December 2023. 9,437 participants five years of age and older were enrolled in the trial
6-K
EX-99.1
VALN
Valneva SE
4 Mar 24
Valneva to Present at Upcoming TD Cowen and Van Lanschot Kempen Healthcare Investor Conferences
4:39pm
, is currently in Phase 3 clinical development and partnered with Pfizer for this study and global commercialization. Recruitment completion
6-K
EX-99.2
VALN
Valneva SE
5 Dec 23
Current report (foreign)
8:50am
EXHIBIT 99.2
Pfizer and Valneva Complete Recruitment for Phase 3 VALOR Trial for Lyme Disease Vaccine Candidate, VLA15
9,437* participants enrolled … (Nasdaq: VALN; Euronext Paris: VLA) today announced that they have completed recruitment for the Phase 3 trial Vaccine Against Lyme for Outdoor
6-K
EX-99.1
avdu8u4tp1w9jj2z942
10 Nov 22
Valneva Reports Nine-Month 2022 Results and Provides Corporate Updates
11:05am
6-K
EX-99.4
kdhneep28va5j244jbxo
5 May 22
Current report (foreign)
4:59pm
6-K
EX-99.3
q9h5z48s1w
25 Mar 22
Valneva Reports Full Year 2021 Results and Provides Corporate Updates
7:24am
20-F
EX-10.7
lku 7h7vc4tss
24 Mar 22
Annual report (foreign)
12:32pm
20-F
ev7jy6k 9p48
24 Mar 22
Annual report (foreign)
12:32pm
424B4
togurcwwqey094622g
1 Nov 21
Prospectus supplement with pricing info
4:06pm
F-1
c7kwoaqilz7y uhok1yr
26 Oct 21
Registration statement (foreign)
5:04pm
DRS
cqbom7omgf6
20 Oct 21
Draft registration statement
12:00am
6-K
EX-99.2
as661hf 7o
18 Oct 21
Valneva Reports Positive Phase 3 Results for Inactivated, Adjuvanted COVID-19 Vaccine Candidate VLA2001
8:00am
6-K
EX-99.1
q973gyvxk8d n48c055b
18 Oct 21
Valneva Reports Positive Phase 3 Results for Inactivated, Adjuvanted COVID-19 Vaccine Candidate VLA2001
8:00am
6-K
EX-99.1
cpcch8vpzfg3
24 Sep 21
Valneva Continues Expansion of Clinical Trials of its Inactivated COVID-19 Vaccine Candidate VLA2001
5:25pm
6-K
EX-99.1
ue151s4ge51ar22d7p
17 Sep 21
Valneva Completes Recruitment of Elderly Participants in Phase 3 Trial of its Inactivated COVID-19 Vaccine
5:25pm
6-K
EX-99.1
ayj8ttjtfplx1qo554
13 Aug 21
Valneva Initiates Further Phase 3 Clinical Trial for its COVID-19 Vaccine Candidate
5:25pm
6-K
EX-99.3
ttnq6h
10 Aug 21
Valneva Reports H1 2021 Financial Results and Provides Business Update
5:25pm
6-K
EX-99.2
07d 5dj76r
10 Aug 21
Valneva Reports H1 2021 Financial Results and Provides Business Update
5:25pm